Discover Oncology, Год журнала: 2024, Номер 15(1)
Опубликована: Окт. 29, 2024
Язык: Английский
Cancers, Год журнала: 2024, Номер 16(17), С. 2975 - 2975
Опубликована: Авг. 27, 2024
Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.
Язык: Английский
Процитировано
9
Advances in medical diagnosis, treatment, and care (AMDTC) book series, Год журнала: 2024, Номер unknown, С. 391 - 418
Опубликована: Авг. 28, 2024
Cancer immunotherapy has emerged as a revolutionary approach in the fight against cancer. Unlike traditional treatments like chemotherapy and radiation, harnesses power of body's own immune system to identify destroy cancer cells. promising therapy, but limitations specificity control hinder its full potential. Synthetic gene circuits offer address these challenges. This chapter emphasizes diverse applications synthetic immunotherapy. Additionally, authors discuss advantages AND gate for minimizing off-target effects, engineered bacteria targeted tumour manipulation, T-cell engineering enhanced anti-tumour activity. Ultimately, therapies are not mutually exclusive. While proven effectiveness accessibility, hold immense promise personalized, long-term solutions.
Язык: Английский
Процитировано
5
Medical Oncology, Год журнала: 2025, Номер 42(2)
Опубликована: Янв. 17, 2025
Abstract Limited advancements in managing malignant brain tumors have resulted poor prognoses for glioblastoma (GBM) patients. Standard treatment involves surgery, radiotherapy, and chemotherapy, which lack specificity damage healthy tissue. Boron-containing compounds, such as boric acid (BA), exhibit diverse biological effects, including anticancer properties. This study aimed to examine whether boron supplementation, BA, can inhibit growth a xenograft animal model. Using MRI-based tumor size measurement, survival rates, hematological, clinical biochemistry analyses, genotoxicity parameters, we assessed the impact of BA. Histopathological, immunohistochemical, immunofluorescence examinations were also conducted. All BA doses (3.25, 6.5, 13 mg kg −1 b.w.) extended compared GBM controls after 14 days, with dose-dependent anti-GBM effect observed MRI analyses. improved hematological (WBC PLT counts) biochemical parameters (LDL-C, CREA, ALP). Histopathological examination revealed significant reduction diameter 6.5 Immunohistochemical staining showed modulation intracytoplasmic Ki67, cytoplasmic CMPK2, GFAP expressions cells post-BA treatment. Additionally, did not increase micronuclei formations, indicating its non-genotoxic nature. In conclusion, targeting suppressor networks demonstrates therapeutic potential
Язык: Английский
Процитировано
0
Cancers, Год журнала: 2025, Номер 17(3), С. 462 - 462
Опубликована: Янв. 29, 2025
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy other blood and solid cancers, these therapies have yielded limited success clinical trials for both newly diagnosed recurrent GBM. A deeper understanding GBM’s resistance to immunotherapy essential enhancing treatment responses translating results seen cancer models. Objectives: In this review, we examine trial outcomes involving ICIs CAR-T GBM explore evasive mechanisms tumor microenvironment. Findings Discussion: Multiple investigating shown poor outcomes, no significant improvement progression-free survival (PFS) or overall (OS). Results from smaller case studies therapy warranted further investigation. However, large-scale robust yet established immunotherapeutic approaches as definitive strategies. Future research should shift focus addressing scarcity functional T cells exploiting abundant myeloid-derived within Conclusions: Translating into effective treatments glioblastoma humans remains a challenge. highly immunosuppressive nature its microenvironment continue hinder innovative approaches. Targeting compartment may lead more sustained responses.
Язык: Английский
Процитировано
0
Ege Tıp Dergisi, Год журнала: 2025, Номер 64(1), С. 184 - 192
Опубликована: Март 12, 2025
Dünya Sağlık Örgütü tarafından derece 4 astrositom olarak sınıflandırılan Glioblastoma Multiform (GBM), merkezi sinir sisteminin en agresif ve yaygın görülen primer beyin tümörüdür. Klinikteki GBM hastaları için mevcut tedavi; rezeksiyonun ardından eş zamanlı uygulanan radyoterapi kemoterapiyi içermektedir. tedavisindeki bu yaklaşımların etkinliği; tümör heterojenliği, glioma kök hücreleri, DNA hasar onarım mekanizmaları kan-beyin bariyeri gibi faktörler nedeniyle yetersiz kalmaktadır. Temozolomid, lipofilik bir ajan olması bariyerini kolaylıkla geçebilmekte özelliği sayesinde tedavisinde etkili kullanılmaktadır. Bununla birlikte, hastaların büyük kısmında nüks meydana gelmekte hastalar Temozolomid’e uzun süre maruz kaldığı tedaviye direnç geliştirmektedir. Günümüzde, eden farklı tedavi yaklaşımı söz konusu değildir. Bu yüzden, hasta sağkalımını uzatacak yeni ajanların araştırılması son önemlidir. Terapötik sistemine iletimi, engellenmekte beyindeki hedeflenen bölgelere erişim, ilaçların geliştirilmesinde zorluklardan birini oluşturmaktadır. Beyin tümörleri bariyerinin ilaç geçirgenliği heterojen yapı sergilemektedir. Sonuç olarak, bariyer geçirgenliğinin modüle edilmesi biyoyararlanımını artırmayı hedefleyen çeşitli stratejiler geliştirilmelidir. Kan-beyin aşılması, hedefe yönelik yaklaşımlarında dikkate alınması gereken önemli konudur. derleme, ile ilişkisini inceleyerek, konuya dair güncel bilgileri ayrıntılı şekilde sunmayı amaçlamaktadır.
Процитировано
0
Aging Cell, Год журнала: 2025, Номер unknown
Опубликована: Апрель 3, 2025
Immunotherapy has transformed the landscape of cancer treatment, with T cell-based strategies at forefront this revolution. However, durability these responses is frequently undermined by two intertwined phenomena: cell exhaustion and senescence. While driven chronic antigen exposure in immunosuppressive tumor microenvironment, leading to a reversible state diminished functionality, senescence reflects more permanent, age- or stress-induced arrest cellular proliferation effector capacity. Together, processes represent formidable barriers sustained anti-tumor immunity. In review, we dissect molecular underpinnings senescence, revealing how dysfunctions synergistically contribute immune evasion resistance across range solid tumors. We explore cutting-edge therapeutic approaches aimed rewiring exhausted senescent phenotypes. These include advances checkpoint blockade, engineering "armored" CAR-T cells, senolytic therapies that selectively eliminate novel interventions reinvigorate system's capacity for eradication. By spotlighting emerging target both provide forward-looking perspective on potential harness rejuvenation. This comprehensive review outlines next frontier immunotherapy: unlocking durable overcoming intrinsic aging exhaustion, ultimately paving way transformative breakthroughs.
Язык: Английский
Процитировано
0
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Апрель 17, 2025
Cancer-associated fibroblasts (CAFs) are integral components of the tumor microenvironment playing key roles in progression, metastasis, and therapeutic resistance. However, challenges persist understanding their heterogeneity, origin, functional diversity. One major obstacle is lack standardized naming conventions for CAF subpopulations, with current systems failing to capture full complexity. Additionally, identification CAFs hindered by absence specific biomarkers, limiting precision diagnostic strategies. In vitro culture conditions often fail maintain vivo characteristics CAFs, which complicates study translation findings clinical practice. Although detection methods, such as antibodies, mRNA probes, single-cell transcriptomics, offer insights into biology, they standardization provide reliable quantitative measures. Furthermore, dynamic interactions between cells, immune cells within TME remain insufficiently understood, role evasion therapy resistance an area ongoing research. Understanding how influence drug response essential developing more effective cancer therapies. This review aims in-depth analysis research, propose future research directions, emphasize need improved CAF-targeted By addressing these gaps, it seeks highlight potential targets overcoming enhancing efficacy treatments.
Язык: Английский
Процитировано
0
Biomedicines, Год журнала: 2024, Номер 12(6), С. 1376 - 1376
Опубликована: Июнь 20, 2024
Glioblastoma multiforme (GBM) is one of the most aggressive forms brain tumor, characterized by a daunting prognosis with life expectancy hovering around 12–16 months. Despite century relentless research, only select few drugs have received approval for tumor treatment, largely due to formidable barrier posed blood–brain barrier. The current standard care involves multifaceted approach combining surgery, irradiation, and chemotherapy. However, recurrence often occurs within months despite these interventions. challenges drug delivery overcoming therapeutic resistance become focal points in treatment tumors are deemed essential recurrence. In recent years, promising wave advanced treatments has emerged, offering glimpse hope overcome limitations existing therapies. This review aims highlight cutting-edge technologies ongoing stages development, providing patients valuable insights guide their choices treatment.
Язык: Английский
Процитировано
1
Cell Biology International, Год журнала: 2024, Номер unknown
Опубликована: Окт. 4, 2024
Abstract Since suppressor/enhancer of Lin‐12‐like (SEL1L) was cloned in 1997, various pieces evidence from lower species suggest it plays a significant role protein degradation via the ubiquitin‐proteasome system. The relevance SEL1L many aspects malignant transformation and tumorigenic events has been subject research, which shown compelling vitro vivo findings relating its altered expression to changes tumor aggressiveness. Endoplasmic Reticulum (ER) cells is crucial for preserving cellular proteostasis by inducing unfolded response (UPR), stress response. A component UPR ER‐associated (ERAD), guards against ER stress‐induced apoptosis removal or misfolded proteins As stabilizer HMG‐CoA reductase 1 (HRD1), one main components ERAD, an important homeostasis. Notably, levels these two fluctuate independently cancer types, yet their affect other associated during pathogenesis. Recent studies have also outlined function medication resistance. This review explores value targeting as novel treatment approach cancer, focusing on molecular processes involvement etiology.
Язык: Английский
Процитировано
1
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Ноя. 28, 2024
Cancer immunotherapy has emerged as a novel clinical therapeutic option for variety of solid tumors over the past decades. The application in primary and metastatic brain continues to grow despite limitations due physiological characteristics immune system within central nervous (CNS) distinct pathological barriers malignant tumors. post-immunotherapy treatment imaging is more complex. In this review, we summarize immunotherapies beyond CNS. We provide an overview current used tumors, including checkpoint inhibitors (ICIs), oncolytic viruses, vaccines, CAR T-cell therapies. focus on criteria assessment response immunotherapy, patterns. discuss advanced techniques evaluation treatment-related complications CNS are described. Lastly, future challenges field explored.
Язык: Английский
Процитировано
1